Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance

Bristol-Myers Squibb CoTrade
iShares Core MSCI EAFE ETFTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs iShares Core MSCI EAFE ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.87 (market cap $129.94B), while iShares Core MSCI EAFE ETF trades at $101.08. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while iShares Core MSCI EAFE ETF pays none. Which is the better fit depends on your goals.

BMYIEFA
Market Cap
$129.94B
Sector
HealthBroad Market / Factor
52-Week High
$65.89$101.09
52-Week Low
$42.60$84.72
Enterprise Value
$163.92B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

iShares Core MSCI EAFE ETF

IEFA, the iShares Core MSCI EAFE ETF, trades at $101.02, up 0.49% today, with a bullish technical signal driven by strong moving average alignment. The ETF focuses on developed international equities outside the U.S. and Canada, offering diversification and a dividend yield of 3.30% (The Motley Fool, 2026-06-17). Recent news highlights its cost efficiency and income appeal compared to peers like EFA and VXUS.

The outlook remains positive due to international diversification benefits and potential Fed rate cuts, but risks include currency fluctuations and geopolitical tensions. Analyst sentiment is favorable, emphasizing lower expense ratios and stable dividend income for long-term investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About iShares Core MSCI EAFE ETF

IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.

Read more on IEFA